Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Ahn-Gook Pharmaceutical Co., Ltd. is a renowned company in the pharmaceutical industry, dedicated to the research, production, and distribution of a wide array of medicinal products. Since its inception, the company has been at the forefront of developing treatments that cater to both acute and chronic health conditions, enriching lives with its innovative healthcare solutions. The company's product line significantly impacts sectors such as cardiovascular, respiratory, and gastrointestinal medicine, offering life-saving drugs and long-term therapy options. With its strong emphasis on research and development, Ahn-Gook Pharmaceutical plays a crucial role in advancing medical science, fostering collaborations with academic institutions and healthcare organizations globally. Its commitment to quality assurance ensures safety and efficacy, bolstering trust among healthcare providers and patients alike. In the financial market, Ahn-Gook Pharmaceutical is a key player on the Korean Stock Exchange, representing the dynamic growth and resilience of South Korea's pharmaceutical sector. The company's steadfast dedication to health improvement and sustainable practices underscores its significant presence in the global healthcare landscape.
€9,930.00
€150.00 (-1.49%)
Live · 05:26 PM
Operating margin is thin at 3.20%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue grew 13.2%, still solid.
At 12284x earnings, the current multiple leaves limited room for execution misses or growth deceleration.
12284.1x earnings, 4812.9x FCF. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
₩330.05B
▲ +13.2% YoY
Net Income (TTM)
₩16.21B
▼ -55.2% YoY
Op. Margin
6.06%
▲ +0.7pp YoY
ROIC
3.87%
▲ +1.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
₩41.44B
▲ +151.9% YoY
Op. Cash Flow (TTM)
₩52.21B
▲ +214.3% YoY
Net Debt
₩19.02B
Cash & Equiv.
₩54.05B
3Y CAGR: +14.3%
Continue Research
At a P/E of 12,284.1 and a price-to-free-cash-flow of 4,812.9, Ahn-Gook Pharmaceutical Co. (001540.XKRX) trades below a two-stage DCF intrinsic value of about KRW 113,637.03 per share, so at KRW 9,930.00 the stock looks undervalued (1,044.4% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Ahn-Gook Pharmaceutical Co. scores 65/100 on Intrinsiqq's quality scorecard (a solid business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about KRW 113,637.03 per share for 001540.XKRX, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around KRW 85,227.77. At today's KRW 9,930.00, that puts the stock about 1,044.4% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Ahn-Gook Pharmaceutical Co. scores 65 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a solid business on these measures. Recent fundamentals include a 6.1% operating margin and a 3.9% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. 001540.XKRX currently trades below its estimated intrinsic value and scores 65/100 on quality (solid). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.